You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
心瑋醫療-B(06609.HK)2024財年虧損大幅縮減88%至1200萬元
格隆匯 03-27 19:40

格隆匯3月27日丨心瑋醫療-B(06609.HK)公告,於2024財政年度,公司錄得收入人民幣2.78億元,同比增長19.6%。儘管受批量採購價格影響及市場競爭導致毛利率下降,公司稅前虧損大幅收窄至人民幣1200萬元,同比減少88.3%。隨着業務規模擴張及成本控制與增效措施成效顯現,銷售及分銷開支與行政開支的費用率降至49.6%(2023年:66.2%)。

年內,爲適應快速變化的市場環境,公司持續推動神經介入業務升級,聚焦差異化治療器械。急性缺血性腦卒中治療器械(如顱內取栓支架、遠端通路導管、顱內血栓抽吸導管及支撐導管等)銷量增長45.5%。出血性腦卒中治療器械及其他介入通路器械收入分別增長104.2%及109.4%。

於海外市場,公司已取得顱內取栓支架、封堵球囊導管、遠端通路導管及微導管的CE或FDA認證,以及26項其他國家或地區的註冊證書。截至目前,公司正於10個國家或地區進行逾40項產品註冊,擴展銷售渠道,爲實現海外銷售長期目標奠定基礎。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account